ERBB2 and cancer: The drug is then delivered to HER2 expressing cancer cells and finally blocks the cancer cell division, resulting in G2/M phase arresting, apoptosis, and reduced proliferation of HER2 positive cancer (Next-Generation Anti–HER2-Antibody Drug Conjugates, ; Rinnerthaler et al., 2019; D'Amico et al., 2019).